Skip to main content

Table 1 Baseline demographic and clinical characteristics of the systemic lupus erythematosus study cohort

From: Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort

Demographic characteristics

 Number of patients

3215

 Women/Men

2925 (91%)/290 (9%)

 Age at SLE diagnosis, mean ± SD

37 ± 13 (range, 19–86 years)

 Age at the time of RELESSER-TRANS inclusion, mean ± SD

48 ± 14 (range, 19–94 years)

 Ethnic groups

Caucasians: 93%/Hispanics: 5.4%/African-Americans: 0.2%/Asians: 0.6%/Others: 0.8%

 Tobacco

Never: 58%/Before: 25%/At the time of RELESSER-TRANS inclusion: 17%

Clinical manifestations

 Constitutional symptoms

Fever 3.6%/Weight loss 9.5%

 Cutaneous

64%

 Arthritis

78%

 Raynaud’s phenomenon

35%

 Vasculitis

10%

 Nephritis

31%

 Gastrointestinal involvement

3%

 Hepatitis

2.8%

 Pericarditis

15%

 Non-ischemic cardiac disease

4.5%

 Neuropsychiatric manifestations

6.5%

 Hematologic

79%

 Lymphadenopathy/Splenomegaly

9.7%/2.9%

 Secondary antiphospholipid syndrome

17%

 SLEDAI score, mean ± SD

2.62 ± 3.69

 SDI score, mean ± SD

1.15 ± 1.68

Immunological laboratory*

 Anti-dsDNA antibody positivity (available data in all patients)

72%

 Hypocomplementemia (available data in all patients)

76.5%

 Anti-Sm antibody positivity (available in 3048 patients)

21%

 Anti-Ro antibody positivity (available in 3109 patients)

40%

 Anti-La antibody positivity (available in 3108 patients)

19%

 Anti-RNP antibody positivity (available in 3095 patients)

25%

 Anticardiolipin antibody positivity [IgM or IgG] (available in 2952 patients)

20%

 Anti-beta 2 glycoprotein 1 [IgM or IgG] (available in 1918 patients)

13.5%

 Lupus anticoagulant (available in 2312 patients)

23%

Treatments**

Corticosteroids

88%

 <10 mg/daily of prednisone or equivalent

46.5%

 10–30 mg/daily

32%

 >30–60 mg/daily

21.5%

Antimalarials

83.5%

Methotrexate

17%

Azathioprine

31%

Cyclophosphamide

20%

Mycophenolate

16%

Intravenous immunoglobulins

4%

Plasmapheresis

1.5%

Rituximab

6%

Antiplatelet therapy

36%

Anticoagulants

14%

  1. Abbreviations: RELESSER-TRANS Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology [SER], cross-sectional phase, SD standard deviation, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, SLE systemic lupus erythematosus, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
  2. *Because this is a retrospective (historical) study, not all analyzed variables were recorded in all included cases. Thus, the percentage for each variable was calculated for only those patients in which the data were documented
  3. ** Treatments recorded in the RELESSER-TRANS registry as “any use” or “use at last visit” (corresponding to the last visit before enrollment) or both